Warren Marcus, PhD, CEO & Co-founder of WiNK Therapeutics, is on a mission to cure Type 1 diabetes using the body’s own natural glucose control system: beta islet cells. A member of our T1D Moonshot Community, Dr. Marcus chatted with us at the recent ADA Scientific Sessions to give us the background on what his company is developing.
🔬 Root Cause Focus: WiNK Therapeutics aims to cure Type 1 diabetes by targeting its root cause, using RNA technology to replace lost beta cells and protect them from autoimmune attacks.
🧬 RNA Technology: Single strands of RNA are used to temporarily remove the brakes on cell proliferation, allowing for the replacement of lost beta cells. Another RNA-based drug helps protect these cells from the immune system.
💪 Personal Motivation: Warren Marcus, PhD, is driven by his grandmother's struggles with diabetes, inspiring him to focus on creating a cure.
🌐 Therapeutics Landscape: The field is evolving with new technologies like stem cell-based methods from Vertex and nanoparticle targeting of beta cells.
🌠 Health Moonshot Community: Being part of the T1D Moonshot Community provides support and camaraderie among CEOs, facilitating idea exchange and connection with investors.
🚀 Future Goals: WiNK Therapeutics is focused on fundraising and completing IND-enabling studies to bring their technology to patients within two to three years.
---
Connect with Health Transformers: www.startuphea...
Become a Health Moonshot Champion: www.startuphea...
Apply to Health Transformer University: www.startuphea...
Connect with StartUpHealth:
Website: www.startuphea...
Instagram: / startuphealth
Twitter: / startuphealth
Podcast: startup-health...
10 сен 2024
